Tubular adenoma cancer risk, cancer risk with biologic and nonbiologic dmards, colon polyp size and cancer risk, dense breasts cancer risk, breast cancer risk calculator, cancer risk with biologic psoriatic arthritis, cancer risk with biological dentist, cancer risk with biological definition, cancer risk with biologic and targeted synthetic dmards for rheumatoid, breast cancer risk, cancer risk with biologic medications, ovarian cancer risk with brca, gail model scale breast cancer risk, cancer risk with biologic and targeted synthetic dmards in ra.
Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register.
Abstract
to investigate the occurrence and relative risk of incident malignancy in patients with rheumatic diseases and previous malignancies treated with biologic and targeted synthetic DMARDs (b/tsDMARDs). Cohort study of patients included in BIOBADASER 3.0 up to 2021, treated with b/tsDMARDs and history of a previous malignancy. Incident cancer was defined as any cancer (new primary, local recurrence or metastases) during the drug exposure. Incidence rate ratios of cancer per 1,000 patients-year (PY) and 95 % confidence interval (CI) were estimated. Rates of incident cancer in tsDMARDs and other bDMARDs versus TNFi were compared. A total of 352 patients from over 9,129 patients recorded in BIOBADASER 3.0 had a history of a previous malignancy. Overall, there were 47 incident malignancies (28 solid cancers, 18 non-melanoma skin cancers and 1 melanoma). The overall rate of incident malignancy was 47.4 (95 % CI 35.6-63.1) events/1,000 PY, ranging between 24.5 events/1000 PY in the anti -CD20 group to 93 events/1000 PY in the anti-CTLA-4 group. We did not find differences in the adjusted rate of incident cancer in patients exposed to JAKi [0.5 (95 % CI 0.2-1.7)], anti-CD20 [0.4(95 % CI 0.1-1)], or anti-IL6 [1.1(95 % CI 0.5-2.4)], anti-CTLA-4 [1.5 (95 % CI 0.7-3.1) or anti-IL17 [0.7 (95 % CI 0.2-2.4) versus TNFi therapy. We did not find differences in the risk of incident cancer in patients with rheumatic diseases and a previous malignancy between TNFi and other b/tsDMARDs. While incident cancers in our cohort were limited, our data is reassuring, awaiting validation in future studies.
Authors (10) : Juan Molina-Collada, Fernando Alonso, Lucía Otero, Cristina Bohórquez, César Díaz Torné, Carolina Pérez García, Juan M Blanco Madrigal, Paloma Vela, José María Álvaro-Gracia, Isabel Castrejón
Source : Seminars in arthritis and rheumatism
Article Information
| Year | 2023 |
| Type | Journal Article |
| DOI | 10.1016/j.semarthrit.2023.152341 |
| ISSN | 1532-866X |
| Volume | 64 |
You can download journal here :
If You have any problem, contact us here
